Chan Zuckerberg Initiative
Imaging Scientists
Imaging scientists play a critical role in developing and sharing advanced imaging technologies, which are central to both biomedical research and clinical practice. CZI’s Imaging Scientists program aims to advance the field of imaging by increasing collaboration between biologists and technology experts and improving the imaging tools that scientists use.
CZI invites applications for its new Imaging Scientists Request for Applications (RFA). These five-year grants will support up to 15 Imaging Scientists who work in imaging core facilities at the interface of biology, microscopy hardware, and imaging software worldwide. We’re looking for engineers, physicists, mathematicians, computer scientists, or biologists who have focused on technology development in either light or electron microscopy, medical imaging, or data analysis fields. Learn more and apply.
Award Amount:
See link below for details
Due Date:
July 30, 2020
Department of Defense
Scleroderma Research Program (SRP)
The FY20 Defense Appropriations Act provides funding to the Department of Defense Scleroderma Research Program (SRP) to support innovative, high-impact scleroderma research.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Development Command (USAMRDC).
The SRP is providing the information in this pre-announcement to allow investigators time to plan and develop ideas for submission to the anticipated FY20 funding opportunities. This pre-announcement should not be construed as an obligation by the Government. The FY20 SRP Program Announcements and General Application Instructions for the following award mechanisms will be posted on the Grants.gov website. Pre-application and application deadlines will be available when the Program Announcements are released.
Applications submitted to the FY20 SRP Idea Development Award must address one or more of the following Focus Areas:
- Development of clinical trial platforms that enable the rapid comparison of different therapeutic approaches on a pilot basis
- Define biomarkers (‘omics and/or molecular markers, cell subsets, imaging, patient-reported outcomes) that help inform choice therapeutics (immunosuppressive/anti-fibrotic) or predict course (morbidity, mortality) and quality of life
- Secondary analysis of genomics and other datasets (scleroderma and datasets from other similar diseases), integration to identify novel targets and biomarkers to create a more analyzable set of data that can be validated in existing or new models
Applications submitted to the FY20 SRP Translational Partnership Research Award must address one or more of the following Focus Areas:
- Understanding the different biological/metabolic pathways that differentiate subsets of patients (gender, age, genetic, clinical phenotype, race/ethnicity)
- Utilizing systems biology and multi-omics approaches for understanding disease heterogeneity, primary prevention, therapeutics, interventions, and screening
- Development of cohorts from diverse populations (longitudinal) to validate potential biomarkers (i.e., replication studies)
- Define biomarkers (‘omics, and/or molecular markers, cell subsets, imaging, patient-reported outcomes) that help inform choice of therapeutics (immunosuppressive/anti-fibrotic) or predict course (morbidity, mortality) and quality of life
- Defining epigenetic changes, multiple cell types, and molecules that mediate pathogenesis
Award Amount:
$450,000 to $750,000
Due Date:
See link below
More Information (SRP)
Department of Defense
Combat Readiness Program (CRRP)
The FY20 Defense Appropriations Act provides funding to the Department of Defense Combat Readiness – Medical Research Program (CRRP) to support military-relevant advanced technology and therapeutic research related to forward-deployable solutions that can promptly address life-threatening injuries, medical threats, and treatments for Service members in current and future battlefield settings.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Broad Agency Announcement/Funding Opportunity is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Development Command (USAMRDC).
The FY20 Congressional language for the CRRP considered research that would enable the Warfighter to better respond to serious injury, as well as solutions to mitigate the long-term effects of battlefield trauma. The CRRP is providing the information in this pre-announcement to allow investigators time to plan and develop ideas for submission to the anticipated FY20 Funding Opportunity.  This pre-announcement should not be construed as an obligation by the Government. The FY20 CRRP Broad Agency Announcement and General Submission Instructions for the following award mechanism will be posted on the Grants.gov website. Pre-application and application deadlines will be available when the Broad Agency Announcement is released.
The FY20 CRRP will solicit research applications addressing at least one of the Focus Areas described below. The Focus Areas broadly describe current needs to ensure readiness for delivering front-line care in combat situations and for delivering medical damage control capability, assets, and lifesaving interventions to address the emerging needs of the Warfighter and Service medics during prolonged and en route care in austere and combat environments, including the acute and early management of combat-related trauma at the point of injury.
Award Amount:
2,000,000.00 Maximum
Due Date:
See link below
More Information (CRRP)
Department of Defense
Pancreatic Cancer Research Program (PCARP)
The FY20 Defense Appropriations Act provides funding to the Department of Defense Pancreatic Cancer Research Program (PCARP) to support a collaborative pancreatic cancer research paradigm that reduces the burden of pancreatic cancer.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Development Command (USAMRDC).
The PCARP is providing the information in this pre-announcement to allow investigators time to plan and develop ideas for submission to the anticipated FY20 funding opportunity. This pre-announcement should not be construed as an obligation by the Government. The FY20 PCARP Program Announcements and General Application Instructions for the following award mechanisms will be posted on the Grants.gov website. Pre-application and application deadlines will be available when the Program Announcements are released.
Applications submitted to the FY20 PCARP must address one or more of the following Focus Areas:
- Understanding precursors, origins, and early progression of pancreatic cancer
- Understanding the events that promote pancreatic cancer metastasis
- Understanding the relationship between oncogenic signaling and the tumor microenvironment that drives drug resistance and therapeutic response
- Integration of biologic and imaging biomarkers to drive more precise and earlier detection and prognosis
- Defining viable tumor burden
- Supportive care and patient-reported outcomes, quality of life, and perspectives during treatment and survivorship
- New drug development targeted toward cancer sensitivity and resistance mechanisms including immune mechanisms of resistance (for correlative studies only)
- Development of pharmacological, immunological, or genetic interception approaches
Award Amount:
$500,000 – $750,000 (2 Awards Available)
Due Date:
See link below
More Information (PCARP)
NASA
Innovative Advanced Concepts (NIAC) Phase I
Appendix 80HQTR20NOA01-21NIAC-A1 seeks NASA Innovative Advanced Concepts (NIAC) Phase I proposals for early stage feasibility studies of visionary concepts that address national, government, and commercial aerospace goals. Concepts are solicited from any field of study that offers a radically different approach or disruptive innovation that may significantly enhance or enable new human or robotic science and exploration missions. Proposed concepts must be framed in terms of a mission context that clearly identifies scientific or technical advancements and associated benefits compared to current approaches. Comparatively high risk and far term, NIAC concepts are transformational investments in future NASA and commercial space capabilities. The entry Technology Readiness Level (TRL) for Phase I concepts should be TRL 2 or lower.
Eligibility:
This Appendix is an Open Announcement. All categories of U.S organizations may apply. Non-U.S. organizations may partner in, or lead, NIAC studies on a no-exchange of funds basis, and subject to NASA’s policy on foreign participation
Award Amount:
$125,000 (12-16 Awards Available)
Due Date:
July 22, 2020
National Endowment for the Humanities (NEH)
Humanities Initiatives Grant Programs
Humanities Initiatives strengthen the teaching and study of the humanities by developing new humanities programs, resources (including those in digital format), or courses, or by enhancing existing ones.
These grants serve:
- Colleges and Universities (new this year)
- Community Colleges
- Hispanic-Serving Institutions
- Historically Black Colleges and Universities
- Tribal Colleges and Universities
Award Amount:
$150,000
Due Date:
July 16, 2020